General MedicationsINJECTIONGeneric
CERUBIDINE
DAUNORUBICIN HYDROCHLORIDE
Standard Dose
EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Key Takeaways
- Primary indication: Review priority: PRIORITY Marketing status: Discontinued
- Approval overview CERUBIDINE is listed in Drugs@FDA under application 050484 (NDA).
- Review priority: PRIORITY Marketing status: Discontinued Active ingredient DAUNORUBICIN HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH AYERST Submission history Latest submission status date: 1994-09-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview CERUBIDINE is listed in Drugs@FDA under application 050484 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient DAUNORUBICIN HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH AYERST Submission history Latest submission status date: 1994-09-01 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.